Modulation of EBI2 signalling and/or local concentrations of CH25H, CYP7B1 and HSD3B7 in the brain and the brain blood vessels might result in disease-modulatory effects with potential therapeutic applications in the treatment of neuroinflammatory diseases including multiple sclerosis. This evidence concerns the gene GPR183 and multiple sclerosis.